MCCULLOCH KEVIN (See Remarks) purchased 1.5% of their position (25K shares) of XERIS BIOPHARMA HOLDINGS, INC. on the open market
Open‑market purchase worth $109.5K — a small addition. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 6/16/2025ACC: 0001867096-25-000118
Officer· See Remarks
Since Mar 2026
+25K
Net shares
Net buyer
$109.5K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
25K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+25K
Price / share
$4.38
Trade value
$109.47K
% of position
1.5%
6/13/2025
1.68M→1.71M
Total
Net shares
+25K
Net value
$109.47K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/13/2025 | P · Purchase | +25K | $4.38 | $109.47K | 1.5% | 1.68M | 1.71M |
| Total | +25K | $109.47K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned2K
Common Stock
IndirectShares owned25K
Total
27K indirect27K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2K | Indirect |
| Common Stock | 25K | Indirect |
| Total | 27K | 27K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported